Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington's disease

Ideggyogyaszati Szemle

Volumn 66, Issue 11-12, 2013, Pages 399-405

  Kincses, Zsigmond Tomás ^a,b   Szabó, Nikoletta ^a,b   Tóth, Eszter ^a   Zádori, Dénes ^a   Faragó, Péter ^a   Németh, Dezso ^c   Janacsek, Karolina ^c   Babos, Magor ^d   Klivényi, Péter ^a   Vécsei, László ^a,e  

^a UNIVERSITY OF SZEGED   (Hungary)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^d Euromedic Diagnostics Hungary Ltd   (Hungary)

^e UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Biomarkers of neurodegeneration; Diffusion paramteres; Huntington's disease

Indexed keywords

ADULT; ARTICLE; CAG REPEAT; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; DIFFUSION WEIGHTED IMAGING; EXTERNAL CAPSULE; EXTREME CAPSULE; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; FRONTAL LOBE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MALE; MIDDLE TEMPORAL GYRUS; NERVE DEGENERATION; PRIMARY MOTOR CORTEX; WHITE MATTER;

ADULT; ANISOTROPY; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; CORPUS CALLOSUM; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED;

EID: 84891953394     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Quarrell OW, Rigby AS, Barron L, et al. Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. J Med Genet 2007;44:e68.
2. Nave DR, Ginestroni A, Tessa C, et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am J Neuroradiol 2010;31:1675-81.
3. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Movement Disord 2006;21:1317-25. (Pubitemid 44613279)
4. Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010;82:201-7.
5. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
6. Puri BK, Bydder GM, Manku MS, et al. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008;36:896-905.
7. Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis in press.
8. Hu Y, Chopra V, Chopra R, et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A 2011;108:17141-6.
9. Papp KV, Kaplan RF, Snyder PJ. Biological markers of cognition in prodromal Huntington's disease: a review. Brain Cogn 2011;77:280-91.
10. Vaccarino AL, Sills T, Anderson KE, et al. Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease. PLoS Curr 2011 3, RRN1250.
11. Majid DS, Aron AR, Thompson W, et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov Disord 2011;26:2544-51.
12. Bohanna I, Georgiou-Karistianis N, Sritharan A, et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav 2011;5:171-80.
13. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82:405-10.
14. Douaud G, Gaura V, Ribeiro MJ, et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 2006;32:1562-75. (Pubitemid 44332291)
15. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999;19:2522-34. (Pubitemid 29162401)
16. Reading SA, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 2005;140:55-62. (Pubitemid 41443496)
17. Muhlau M, Gaser C, Wohlschlager AM, et al. Striatal gray matter loss in Huntington's disease is leftward biased. Mov Disord 2007;22:1169-73. (Pubitemid 47067229)
18. Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213-20. (Pubitemid 38183526)
19. Henley SM, Wild EJ, Hobbs NZ, et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol 2009;256:203-12.
20. Ruocco HH, Lopes-Cendes I, Li LM, Santos-Silva M, Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz J Med Biol Res 2006;39:1129-36.
21. Rosas HD, Lee SY, Bender AC, et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage 2010;49:2995-3004.
22. Weaver KE, Richards TL, Liang O, et al. Longitudinal diffusion tensor imaging in Huntington's Disease. Exp Neurol 2009;216:525-9.
23. Kloppel S, Draganski B, Golding CV, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008;131:196-204.
24. Stoffers D, Sheldon S, Kuperman JM, et al. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology 2010;74:1208-16.
25. Gardian G, Vecsei L. Huntington's disease: pathomechanism and therapeutic perspectives. J Neural Transm 2004;111:1485-94. (Pubitemid 39468401)
26. Racsmány M, Lukács Á, Németh D, Pléh C. A verbális munkamemória magyar nyelvu{combining double acute accent} vizsgálóeljárásai (Hungarian diagnostic tools of verbal working memory functions). Magyar Pszichológiai Szemle (Hungarian Review of Psychology) 2005;60:479-506.
27. Isaacs EB, Vargha-Khadem F. Differential course of development of spatial and verbal memory span: A normative study. British Journal of Developmental Psychology 1989;7:377-80.
28. Janacsek K, Tánczos T, Mészáros T, Németh D. The Hungarian version of Listening Span task. Magyar Pszichológiai Szemle (Hungarian Review of Psychology) 2009;64:385-406.
29. Troyer AK, Moscovitch M, Wincour G, Alexander MP, Stuss D. Clustering and switching on verbal fluency: The effects of focal frontal- and temporal-lobe lesions. Neuropsychologia 1998;36:499-504. (Pubitemid 28342185)
30. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143-55. (Pubitemid 35253488)
31. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
32. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25. (Pubitemid 34020610)
33. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83-98.
34. Sun SW, Liang HF, Trinkaus K, et al. Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 2006;55:302-308. (Pubitemid 43238098)
35. Kim JH, Budde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis 2006;21:626-32. (Pubitemid 43277544)
36. Mascalchi M, Lolli F, Nave DR, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004;232:867-73. (Pubitemid 39100275)
37. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21:1317-25. (Pubitemid 44613279)
38. Sritharan A, Egan GF, Johnston L, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 2010;81:257-62.
39. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72. (Pubitemid 38943780)
40. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-7. (Pubitemid 23231489)
41. Taherzadeh-Fard E, Saft C, Wieczorek S, Epplen JT, Anting L. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 2010;11:435-9.
42. Arnting L, Haghikia A, Taherzadeh-Fard E, et al. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) 2010;88:431-6.
43. Coppede F, Migheli F, Ceravolo R, et al. The hOGG1 Ser326Cys polymorphism and Huntington's disease. Toxicology 2010;278:199-203.
44. Henley SM, Ridgway G R, Scahill RI, et al. Pitfalls in the use of voxel-based morphometry as a biomarker: examples from huntington disease. AJNR Am J Neuroradiol 2010;31:711-9.
45. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-77. (Pubitemid 38443548)